Your session is about to expire
← Back to Search
CB-103 + Venetoclax for Advanced Cancer
Study Summary
This trial is testing a combination of drugs to treat advanced ACC tumors and improve survival.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or restricted in physically strenuous activity but can do light work.I agree to use birth control during the study.I currently have an active infection (bacterial, fungal, or viral).I have finished radiotherapy and recovered from its immediate side effects.I have another cancer that won't affect this treatment's safety or results.I have brain metastases or carcinomatous meningitis that are untreated or causing symptoms.I am 18 years old or older.I am a woman who can have children and have a negative pregnancy test taken within the last week.I have not had major surgery in the last 14 days.I am on blood thinners that need regular INR checks.I have a confirmed diagnosis of advanced or incurable adenoid cystic carcinoma.I can swallow pills.I have a digestive issue that affects how my body absorbs medication.I have had treatment for brain or CNS cancer spread and meet certain conditions.I have not had VEGFR TKI therapy but may have had chemotherapy for curative purposes.I have secured a way to pay for or obtain Lenvatinib for the study's duration.I have previously received specific cancer treatments targeting blood vessel growth.My organ and bone marrow functions are within normal ranges.I have recovered from my last chemotherapy and followed the waiting period.My cancer has a NOTCH mutation.
- Group 1: Experimental: Cohort 1A - CB-103 + Abemaciclib
- Group 2: Experimental: Cohort 2B- Lenvatinib + CB-103
- Group 3: Experimental: Cohort 1B - CB-103 + Abemaciclib
- Group 4: Experimental: Cohort 2A- Lenvatinib + CB-103
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this investigation currently enrolling participants?
"Unfortunately, this clinical trial is no longer actively recruiting. The details were first posted on April 15th 2023 and the last update was made on March 14th of the same year. Despite that, there are currently 2497 other medical studies searching for participants to join their trials."
What is the ultimate goal of this research endeavor?
"The primary endpoint of this experiment, which will be measured over a 4-month period, is Progression Free Survival (PFS) for Cohort 2. Other outcomes that are being examined include Overall Response Rate (ORR), as defined by RECIST v1.1; Overall Survival (OS); and Duration of Overall Response (DOR). OS measures the time elapsed between study registration and death due to any cause or last known date alive if censored, while DOR tracks the time from when CR or PR criteria are first recorded until disease progression occurs. In cases where no events have been reported yet participants will be censured at their"
Share this study with friends
Copy Link
Messenger